Glaukos leans on iDose TR repeat-dosing nod as it pitches glaucoma pipeline

Glaukos is using its latest corporate presentation to argue that its glaucoma franchise has room to grow beyond a single marketed implant. The company's own summary of the deck names the US regulatory decision on iDose TR, a travoprost implant for open-angle glaucoma and ocular hypertension, as the central proof point. CompePharma did not have the full presentation, so this report relies on that summary.

According to the summary, the US Food and Drug Administration cleared iDose TR for repeat administration in January 2026. The company also cites a new Phase 3 analysis in which the implant was non-inferior to topical timolol at three years. The summary gives no sales, pricing or uptake numbers, so the commercial effect of either point cannot be sized from the material available. The trial result is company-reported and has not been independently checked here.

The deck also looks to what comes next. The company says it filed an IND amendment in December 2025 for a next-generation iDose product, and that Phase 3b enrolment for it is complete. It also reports Phase 2a results for iDose TREX and iDose TRIO. Neither is FDA-approved, and both are far from the market.

The headline on the company's material also mentions Epioxa and a 14-program pipeline. The summary supplied no detail on either, so CompePharma does not describe them. Glaukos calls itself a drug-and-device company focused on interventional glaucoma and keratoconus.